BTG reiterates full-year guidance

16th Jul 2014 11:41

- FY revenue guidance unchanged- Trading in line- US investigating LC BeadHealthcare company BTG has left its full-year revenue guidance unchanged, saying trading has been in line with expectations.Full-year revenue is expected to be in the £330m to £345m range, despite the recent weakening of the US dollar versus sterling, according to a trading update for the period covering April 1st to July 15th.The company said an increase in the number of US hospitals using the EKOS blood clot treatment products and the Food and Drug Administration clearance of the EkoSonic endovascular system for the treatment of pulmonary embolism, supported growth. The group added that the US launch of the varicose veins treatment Varithena continues on track.Interventional oncology revenues overall were also line with expectations. "We have made a good start to the financial year, with revenues across the business growing as expected," said Chief Executive Louise Makin, adding that the firm is "well positioned to deliver sustainable profitable growth".However, BTG has received a subpoena from the US Department of Justice, seeking documents in relation to an investigation into interventional medicine LC Bead, covering the period since 2003. BTG said is co-operating fully with this investigation and at this time is unable to predict its scope, duration or outcome. RD